Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose by Rossi, Andrés Hugo et al.
Journal Pre-proof
Sputnik V Vaccine Elicits Seroconversion and Neutralizing Capacity to SARS CoV-2
after a Single Dose
Andres H. Rossi, Ph.D., Diego S. Ojeda, Ph.D., Augusto Varese, Ph.D., Lautaro
Sanchez, M.Sc., Maria M. Gonzalez Lopez Ledesma, Ph.D., Ignacio Mazzitelli, M.D.,
Anabel Alvarez Juliá, Ph.D., Santiago Oviedo Rouco, Ph.D., Horacio M. Pallarés,
M.Sc., Guadalupe S. Costa Navarro, M.Sc., Natali Rasetto, M.Sc., Corina I. Garcia,
Ph.D., Shirley D. Wenker, Ph.D., Lila Y. Ramis, M.D., Magalí G. Bialer, Ph.D., Maria
Jose de Leone, Ph.D., C. Esteban Hernando, Ph.D., Santiago Sosa, M.Sc., Luciana
Bianchimano, M.Sc., Antonella Rios, M.Sc., Maria Soledad Treffinger Cienfuegos,
M.Sc., Julio J. Caramelo, Ph.D., Yesica Longueira, M.Sc., Natalia Laufer, Ph.D.,
Diego Alvarez, Ph.D., Jorge Carradori, M.D., Dariana Pedrozza, M.D., Alejandra
Rima, M.D., Cecilia Echegoyen, M.D., Regina Ercole, M.D., Paula Gelpi, M.D.,
Susana Marchetti, M.D., Martín Zubieta, M.D., Guillermo Docena, Ph.D., Nicolas
Kreplak, M.D., Marcelo Yanovsky, Ph.D., Jorge Geffner, Ph.D., Marina Pifano, Ph.D.,




To appear in: Cell Reports Medicine
Received Date: 6 May 2021
Revised Date: 22 June 2021
Accepted Date: 5 July 2021
Please cite this article as: Rossi, A.H., Ojeda, D.S., Varese, A., Sanchez, L., Gonzalez Lopez
Ledesma, M.M, Mazzitelli, I., Juliá, A.A., Rouco, S.O., Pallarés, H.M., Costa Navarro, G.S., Rasetto,
N., Garcia, C.I., Wenker, S.D., Ramis, L.Y., Bialer, M.G., Jose de Leone, M., Hernando, C.E., Sosa,
S., Bianchimano, L., Rios, A., Treffinger Cienfuegos, M.S., Caramelo, J.J., Longueira, Y., Laufer, N.,
Alvarez, D., Carradori, J., Pedrozza, D., Rima, A., Echegoyen, C., Ercole, R., Gelpi, P., Marchetti, S.,
Zubieta, M., Docena, G., Kreplak, N., Yanovsky, M., Geffner, J., Pifano, M., Gamarnik, A.V., Sputnik
V Vaccine Elicits Seroconversion and Neutralizing Capacity to SARS CoV-2 after a Single Dose, Cell
Reports Medicine (2021), doi: https://doi.org/10.1016/j.xcrm.2021.100359.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.













Sputnik V Vaccine Elicits Seroconversion and Neutralizing Capacity  
to SARS CoV-2 after a Single Dose 
 
Andres H. Rossi, Ph.D.1*, Diego S. Ojeda, Ph.D.1*, Augusto Varese, Ph.D. 2, Lautaro Sanchez M.Sc.1, 
Maria M Gonzalez Lopez Ledesma, Ph.D.1, Ignacio Mazzitelli M.D.2, Anabel Alvarez Juliá, Ph.D.1, 
Santiago Oviedo Rouco, Ph.D.1, Horacio M. Pallarés M.Sc.1, Guadalupe S. Costa Navarro M.Sc.1, Natali 
Rasetto M.Sc.1, Corina I. Garcia, Ph.D.1, Shirley D. Wenker, Ph.D.1, Lila Y. Ramis M.D.1, Magalí G. 
Bialer, Ph.D.1, Maria Jose de Leone, Ph.D.1, C. Esteban Hernando, Ph.D.1, Santiago Sosa M.Sc.1, 
Luciana Bianchimano M.Sc.1, Antonella Rios M.Sc.1, Maria Soledad Treffinger Cienfuegos M.Sc.1, Julio 
J. Caramelo, Ph.D.1, Yesica Longueira M.Sc.2,3, Natalia Laufer, Ph.D.2,3, Diego Alvarez, Ph.D.4, Jorge 
Carradori M.D.5, Dariana Pedrozza M.D.6, Alejandra Rima M.D.7, Cecilia Echegoyen M.D.8, Regina 
Ercole M.D.9, Paula Gelpi M.D.10, Susana Marchetti M.D.11, Martín Zubieta M.D.12, Guillermo Docena, 
Ph.D.13, Nicolas Kreplak M.D.14, Marcelo Yanovsky, Ph.D.1, Jorge Geffner, Ph.D.2, Marina Pifano 
Ph.D.14, and Andrea V. Gamarnik, Ph.D.1 
 
1 Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina 
2 Universidad de Buenos Aires, Facultad de Medicina, Instituto de Investigaciones Biomédicas en 
Retrovirus y SIDA (INBIRS-CONICET), Argentina.  
3 Biobanco de Enfermedades Infecciosas (INBIRS-UBA-CONICET), Argentina. 
4 Instituto de Investigaciones Biotecnológicas, Univ. Nacional de San Martín-CONICET, Argentina. 
5 Laboratorio Lemos S.R.L, Buenos Aires, Argentina. 
6 Hospital Interzonal General de Agudos Dr Pedro Fiorito, Provincia de Buenos Aires, Argentina 
7 Hospital Interzonal General de Agudos Evita Provincia de Buenos Aires, Argentina 
8 Hospital Interzonal General de Agudos  Prof. Dr. Rodolfo Rossi, Provincia de Buenos Aires, Argentina 
9 Hospital Interzonal Especializado de Agudos y Crónicos San Juan de Dios, Provincia de Buenos Aires, 
Argentina 
10 Hospital Interzonal General de Agudos San Roque, Provincia de Buenos Aires, Argentina 
11 Hospital Interzonal General de Agudos San Martín, Provincia de Buenos Aires, Argentina 
12 Hospital de Alta Complejidad El Cruce “Nestor Kirchner”, Provincia de Buenos Aires, Argentina 
13 Instituto de Estudios Inmunológicos y Fisiopatológicos, Facultad de Ciencias Exactas, Universidad 
Nacional de La Plata, CONICET-CIC, La Plata, Argentina 
14 Ministerio de Salud de Provincia de Buenos Aires, Argentina 
* These authors contributed equally to this work 












Massive vaccination offers great promise for halting the global COVID-19 pandemic. However, 
limited supply and uneven vaccine distribution create an urgent need to optimize vaccination 
strategies. We evaluate SARS-CoV-2-specific antibody responses after Sputnik V vaccination of 
healthcare workers in Argentina, measuring IgG anti-spike titers and neutralizing capacity after 
one and two doses in a cohort of naïve or previously infected volunteers. By 21 days after 
receiving the first dose of vaccine, 94% of naïve participants develop spike-specific IgG 
antibodies. A single Sputnik V dose elicits higher antibody levels and virus neutralizing capacity 
in previously infected individuals than in naïve ones receiving the full two-dose schedule. The 
high seroconversion rate after a single dose in naïve participants suggests a benefit of delaying 
second dose administration to increase the number of people vaccinated. The data presented 
provide information for guiding public health decisions in light of the current global health 
emergency. 
Introduction 
Sputnik V (Gam-COVID-Vac) is a combined vector vaccine based on recombinant adenovirus 
(rAd) type 26 and rAd5 1. A two-dose protocol displays 91.6% efficacy against COVID-19 2. In 
the context of the current pandemic, an important question is whether administration of a single 
Sputnik V dose would achieve a greater public health benefit than a two-dose protocol, allowing 
protection of a larger population more quickly. The vaccine developed by AstraZeneca, also a 
two-dose, single rAd-vectored vaccine, showed 76.0% (59.3–85.9%) efficacy after a single 
standard dose 3, supporting a longer interval between the two doses. In the case of the mRNA 
vaccines, mRNA-1273 (Moderna) and BNT162b2 (Pfizer), individuals with prior infection might 
acquire sufficient immunity after a single dose, with no apparent benefit of a two-dose protocol 
4,5.  
Results 
We evaluated antibody responses and viral neutralizing capacity in participants receiving one 
and two doses of Sputnik V, with or without prior SARS CoV-2 infection (N=227 and N=62, 
respectively). Plasma samples were taken on three occasions: before vaccination (baseline), 21 
days after the first dose and 21 days after the second dose. SARS CoV-2 spike IgG was 
measured using a previously described enzyme-linked immunosorbent assay by titration 6 and 








laboratories7. Virus neutralizing antibodies were evaluated using a wild-type (WT) SARS CoV-2 
and a pseudotyped VSV spike expressing GFP 8.  
After the first dose of Sputnik V, 94% of seronegative participants at baseline showed a positive 
SARS CoV-2 IgG response with a geometric mean titer (GMT) of 244 (CI95%, 180–328) (Figure 
1A). Segregation of participants by age showed seroconversion in 96% and 89% of individuals 
under or over 60 years old, respectively (Figure 1B). After the second dose, 100% of 
participants showed seroconversion with a GMT of 2148 (CI95% 1742–2649).  
Participants with SARS CoV-2 antibodies at baseline developed high antibody titers within 21 
days of receiving the first vaccine dose. The GMTs were 531 (CI95%, 380–742) before and 
9850 (CI95%, 8460–11480) after the first dose, showing a 19-fold increase in specific antibody 
levels. By contrast, IgG anti-spike titers after one or two doses were not significantly different: 
GMTs of 9850 (CI95%, 8460–11480) and 9590 (CI95%, 7410–12408) after one and two doses, 
respectively.  
As reference for comparison among laboratories, IgG levels were expressed as International 
Units (IU) after normalization with the WHO International Standard for anti-SARS-CoV-2 
Antibody (Figure 1C). The geometric mean (GM) of IgG concentrations in IU/ml was 104.2 
(CI95%, 92.3–157.5) after the first dose and 787.8 (CI95%, 626.0–936.2) after the second dose 
in naïve individuals, and 181.1 (CI95%, 105.2–243.7), 6,356 (CI95%, 5,409–14,763) and 5,609 
(CI95% 3,621–8,496) for baseline, one and two doses, respectively, in previously infected 
individuals.  
Notably, antibody titers after one dose in participants with preexisting immunity were 
significantly higher than those in naïve vaccinees receiving one or even two doses (P < 0.0001, 
two-tailed Mann Whitney test). GMTs for previously infected participants after one dose were 
40- and 4.6-fold higher than those for naïve individuals receiving one or two doses, respectively 
(Figure 1A). This highlights the robust response to vaccination of previously infected individuals, 
suggesting that naturally acquired immunity might be enhanced sufficiently by a single dose, in 
agreement with recent studies using mRNA vaccines 4,5. 
Neutralizing capacity was evaluated by measuring antibody neutralizing titers for seronegative 
and seropositive individuals at baseline, using the wild type SARS-CoV-2 or CoV2pp GFP 
pseudovirus infection. For the wild type SARS-CoV-2, neutralization titers were defined as the 
highest serum dilution without any cytopathic effect on the monolayer, and for the pseudotyped 








and for 50% inhibition of infection IC50 see supplemental Figure S1). At 21 days after 
administration of the first dose, neutralizing antibodies were detected in 90% of naïve 
participants (seronegative at baselines), with GM neutralizing titers of 12 (CI95%, 10–14) with 
WT SARS-CoV-2 (Figure 2, left panel). Neutralizing GM titers after the complete two-dose 
vaccine protocol in naïve individuals was 42 (IC95%, 33–53) (Figure 2, left panel), which was 
higher than that observed for convalescent individuals (seropositive at baseline) prior to 
vaccination that was 28 (CI95%, 23–40) (Figure 2, right panel). Notably, a robust increase in 
neutralizing antibody activity was observed after a single vaccine dose in participants with prior 
infection. In this regard neutralizing GM titers were 500 (CI95% 341-732) and 782 (IC95% 557-
1099) following infections with the WT and pseudotype virus, respectively (Figure 2, right panel), 
indicating that a single dose of the vaccine triggers a large production of neutralizing antibodies 
in convalescent individuals, which did not increase after a second dose. 
 
Conclusion 
This study provides new data about antibody responses to Sputnik V vaccine in SARS CoV-2 
naïve and previously infected volunteers. We observed a high seroconversion rate following a 
single vaccine dose in naïve individuals. A global 94% of vaccinees elicited specific anti-spike 
antibody responses, with 90% displaying WT virus neutralizing capacity. Importantly, a single 
dose of Sputnik V vaccine caused a fast and robust immune response in seropositive 
participants, with neutralizing titers that exceeded those found in seronegative participants who 
received two doses. Although a protective role of anti-spike antibodies against COVID-19 has 
been reported, the level of protection required for a beneficial outcome during infection is 
uncertain, and further efficacy studies combined with quantitative information on levels of anti-
spike antibodies are needed to define the minimum threshold required for protection. 
Presentation of our data in IU allows comparison of measurements obtained using different 
technologies, helping to define antibody levels associated with protection after vaccination. 
Evidence based on quantitative information will guide vaccine deployment strategies in the face 
of worldwide vaccine supply restriction. 
Limitations of study 
This study shows high humoral responses after Sputnik V administration using a cohort of 288 
volunteers from over 200,000 vaccinated healthcare workers. However, an efficacy study has 








and to define correlates with antibody titers. In addition, follow up studies are necessary to 




Figure 1. Immune response to SARS-CoV-2 Sputnik V Vaccine. Panel A shows quantitative 
SARS-CoV-2 spike antibody titers for 288 participants, with or without prior infection (indicated 
as seropositive or seronegative at baseline, respectively). Measurements were performed 
before vaccination (baseline), 21 days after the first dose and 21 days after the second dose. 
Geometric means with 95% confidence intervals are shown. The Mann-Whitney U test was 
used to compare at various time points antibody titers. Statistical significance is shown with the 
following notations: ****:p < 0.0001; ns: not significant. Panel B shows seroconvertion after one 
dose in participants > or < that 60 years old. Panel C shows quantification of antibody levels by 
International WHO Standard.  
Figure 2 Neutralizing capacity with and without prior SARS-CoV-2 infection after one and 
two doses of Sputnik V vaccine. Neutralizing titers were measured by 80% inhibition for the 
pseudotyped virus (CoV-2pp-GFP) in 232 participants. For WT SARS-CoV-2, neutralization titer 
was defined as the highest serum dilution without any cytopathic effect on the monolayer. Titers 
at baseline, and 21 days after 1 or 2 doses are shown. Left and right panels display data from 
individuals that were seronegative or seropositive at baseline, as indicated on the top 
respectively. Geometric means with 95% confidence intervals are shown in dash lines. The 
Mann-Whitney U test was used to compare at various time points antibody titers. Statistical 
significance is shown with the following notations: ****:p < 0.0001; ns: not significant. 
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Experimental model and subject details 
 Human subjects and samples 
This study monitors the humoral immune response over time in health care workers immunized 
with Sputnik V vaccine. Study enrollment started in January 2021 and is ongoing. Ethical 
approval was obtained from the central committee of the Ministry of Health of Buenos Aires and 
all participants provided written informed consent prior to collection of data and specimen 
(Cod#2021-00983502). Blood was collected by venipuncture into SST tubes (BD Sciences) for 
serum and stored at −20°C. All specimens were de-identified prior to processing and antibody 
testing for all serum specimens.  
Cell lines 
Vero E6 cells (ATCC) and 293T ACE2/TMPRSS2 cells, kindly provided by Dr. Benhur Lee, were 
cultured at 37°C in 5% CO2 in Dulbecco’s Modified Eagle’s high glucose medium (Thermo 
Fisher Scientific) supplemented with 10% fetal bovine serum (FBS) (Gibco). 
Recombinant VSV 
Viral stocks (VSV-eGFP-SARS-CoV-2), generated in Sean Whelan laboratory8, were amplified 
in our laboratory using 293T ACE2/TMPRSS2 cells at an MOI of 0.01 in Dulbecco’s Modified 
Eagle’s medium containing 2% FBS at 37ºC. Viral supernatants were harvested upon extensive 
cytopathic effect and GFP positive cells. The media was clarified by centrifugation at 1,000 x g 
for 5 min. Viral stocks were titrated by fluorescence forming units per milliliter (UFF/ml) in Vero 
cell line. Aliquots were maintained at -80ºC. 
SARS-CoV-2 
SARS-CoV-2 strain 2019 hCoV-19/Argentina/PAIS-G0001/2020 was obtained from Dr. Sandra 
Gallegos (InViV working group). Virus was passaged in Vero E6 cells. Work with SARS-CoV-2 




SARS-CoV-2 antibody ELISA  
Antibodies to SARS-CoV-2 spike protein were detected using an established two step ELISA 
previously described6. This assay has plates coated with a mixture of spike and the receptor 
binding domain (RBD). For end point titrations, samples were serially diluted in IgG SARS-CoV-
2 negative serum or fetal bovine serum (FBS) from 1/50 to 1/12800. The SARS-CoV-2 antibody 








extrapolation of the OD 450 nm value on a calibration curve. For construction of the calibration 
curve, we determined OD 450 nm of serial dilutions of the WHO International Standard for anti-
SARS-CoV-2 immunoglobulin. The linear range used was 0.2-1.5 OD 450nm. Therefore, we 
performed serial dilutions of the samples in order to find conditions where the OD 450nm of 
each sample fit adequately in the linear range. 
SARS-CoV 2 neutralization assay  
Serum samples were heat-inactivated at 56°C for 30min and serial dilutions from 1/2 to 1/8192 
were incubated for 1hs at 37ºC in the presence of WT SARS-CoV-2 (hCoV-19/Argentina/PAIS-
G0001/2020, GISAID Accession ID: EPI_ISL_499083) in DMEM 2% FBS. Fifty µl of the 
mixtures were then deposited over Vero cells monolayers for an hour at 37°C (MOI=0.01). 
Infectious media was removed and replaced for DMEM 2% FBS. After 72 hs, cells were fixed 
with PFA 4% (4°C 20min) and stained with crystal violet solution in methanol. The cytopathic 
effect (CPE) of the virus on the cell monolayer was assessed visually, if even a minor damage 
to the monolayer (1-2 «plaques») was observed in the well, this well was considered as a well 
with a manifestation of CPE. Neutralization titer was defined as the highest serum dilution 
without any CPE in two of three replicable wells.  
Pseudovirus neutralization assay 
Neutralization assays were carried out with SARS-CoV-2 pseudotyped particles (CoV2pp-GFP), 
generated in Sean Whelan laboratory8. CoV2pp-GFP carries vesicular stomatitis virus as viral 
backbone, bearing the E gene in place of its G glycoprotein (VSV-eGFP-SARS-CoV-2), and 
expresses full length wild type spike from Wuhan on its envelope. Vero cells were used for 
these assays. Cells were maintained with DMEM high glucose with 10% FBS and were seeded 
in a 96-well plate the day before infection. Patient sera were heat inactivated at 56°C for 30 
minutes and serially diluted in DMEM high glucose medium. Serum neutralizations were 
performed by first diluting the inactivated sample 2-folds and continuing with a 2-fold serial 
dilution. A pre-titrated amount of pseudotyped particles was incubated with a 2-fold serial 
dilution of patient sera for 1 h at 37ºC prior to infection. Subsequently, cells were fixed in 4% 
formaldehyde containing 2 μg/mL DAPI nuclear stain (Invitrogen) for 1 hour at room 
temperature, and fixative was replaced with PBS. Images were acquired with the InCell 2000 
Analyzer (GE Healthcare) automated microscope in both the DAPI and FITC channels to 
visualize nuclei and infected cells (i.e., eGFP-positive cells), respectively (4X objective, 4 fields 








of the InCell Analyzer 2000 Workstation Software (GE Healthcare). GFP-positive cells were 
identified in the FITC channel using the top-hat segmentation method and subsequently counted 
within the InCell Workstation software. Absolute inhibitory concentrations (absIC) values were 
calculated for all patient sera samples by modeling a 4-parameter logistic (4PL) regression with 
GraphPad Prism 8. The 4PL model describes the sigmoid-shaped response pattern. For clarity, 
it is assumed that the response can be expressed so that the slope increases as the 
concentration increase. Absolute inhibitory concentration (absIC) was calculated as the 
corresponding point between the 0% and 100% assay controls. Eighty % inhibition were defined 
by the controls for all the samples on the same plate. For example, the absIC80 would be the 
point at which the curve matches inhibition equal to exactly 80% of the 100% assay control 
relative to the assay minimum. Furthermore, 50% inhibition was also calculated by modeling a 
4-parameter logistic (4PL) regression with GraphPad Prism 8. 
Quantification and statistical analysis 
All statistical tests and plots were performed using GraphPad Prism 8.0 software. Comparisons 
of the antibody titers at various time points were made using the Mann Whitney U test in Figure 
1A, Figure 2 and Figure 1S. Statistical significance is shown in the figure legends with the 
following notations: ****:p < 0.0001; ns: not significant. Geometric means with 95% confidence 
intervals were calculated in all time points. In all figures “N” represents the number of human 
serum sample tested. 
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- First dose of Sputnik V results in 94% seroconversion rate in naïve individuals  
- A second dose greatly increases antibody titers and neutralizing capacity 
- One dose in seropositive individuals elicits higher titers than two doses in naïve  




Rossi et al. provide data on antibody responses to Sputnik V vaccine in naïve and 
previously infected volunteers. This study shows a high seroconversion rate following 
the first dose in naïve individuals. In seropositive participants a single dose of Sputnik V 
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